| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2003.11.126 |
| P698 | PubMed publication ID | 12775730 |
| P2093 | author name string | Ramesh K Ramanathan | |
| Daniel G Haller | |||
| Lowell L Hart | |||
| Mace L Rothenberg | |||
| Jordan D Berlin | |||
| Sunil Gupta | |||
| John L Marshall | |||
| Amit M Oza | |||
| Brent G Burger | |||
| Carlos A Garay | |||
| Nathalie Le Bail | |||
| Robert H Bigelow | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| colorectal cancer | Q188874 | ||
| colorectal carcinoma | Q25493920 | ||
| phase III clinical trial | Q42824827 | ||
| irinotecan | Q412197 | ||
| oxaliplatin | Q422327 | ||
| P304 | page(s) | 2059-2069 | |
| P577 | publication date | 2003-06-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial | |
| P478 | volume | 21 |
| Q42916333 | A Multicenter Phase-II Study of 5-FU, Leucovorin and Oxaliplatin (FOLFOX6) in Patients with Pretreated Metastatic Colorectal Cancer |
| Q49194716 | A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine |
| Q46501921 | A Phase II study of oxaliplatin in urothelial cancer |
| Q33847443 | A dual-targeting, p53-independent, apoptosis-inducing platinum(II) anticancer complex, [Pt(BDI(QQ))]Cl |
| Q83061757 | A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience |
| Q31080865 | A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer |
| Q36125075 | A panel discussion of controversies and challenges in the adjuvant treatment of colon cancer. |
| Q104557013 | A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer |
| Q34910416 | A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer |
| Q34099365 | A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors |
| Q46919611 | A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC). |
| Q35691981 | A phase II study of oxaliplatin with 5-FU/folinic acid and concomitant radiotherapy as a preoperative treatment in patients with locally advanced rectal cancer |
| Q33390957 | A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study |
| Q37730640 | A postauthorization survey to document the therapeutic management of oxaliplatin as a first-line chemotherapy regimen in South Africa in patients with metastatic colorectal cancer |
| Q24811929 | A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy |
| Q54285333 | A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. |
| Q53648255 | A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer. |
| Q45923777 | A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. |
| Q48194389 | A rat model of FOLFOX-induced neuropathy: effects of oral dimiracetam in comparison with duloxetine and pregabalin |
| Q35906940 | A review of oxaliplatin and its clinical use in colorectal cancer |
| Q38204277 | A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration |
| Q35923181 | Accelerated approval of oncology products: a decade of experience |
| Q26771390 | Advances in drug delivery system for platinum agents based combination therapy |
| Q50041173 | An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma |
| Q89828968 | An empirical investigation of time-varying cost-effectiveness across the product life cycle |
| Q36530731 | Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies |
| Q35891724 | Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer. |
| Q36610680 | Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. |
| Q40184667 | Atypical presentation of fever as hypersensitivity reaction to oxaliplatin |
| Q36106736 | Benefit-risk assessment of irinotecan in advanced colorectal cancer |
| Q37159492 | Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer. |
| Q37307590 | Bevacizumab in the therapy for refractory metastatic colorectal cancer |
| Q36521850 | Biological agents versus chemotherapy in the treatment of colorectal cancer |
| Q36256390 | Broad funding for oxaliplatin in Ontario (finally!). |
| Q36861592 | Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin |
| Q81086290 | Cancers of the large bowel and hepatobiliary tract |
| Q33729092 | Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04 |
| Q46542857 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study |
| Q37154737 | Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence |
| Q30436646 | Chemoradiotherapy for gastrointestinal cancers |
| Q36788478 | Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future |
| Q53855896 | Chemotherapy of Metastatic Colorectal Cancer. |
| Q36485454 | Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer |
| Q37602291 | Chemotherapy, which drugs and when |
| Q37799918 | Chemotherapy: which drug and when? |
| Q53085418 | Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study. |
| Q35623301 | Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial |
| Q45091068 | Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer |
| Q92436380 | Clinical value of an adenosine triphosphate-based chemotherapy response assay in resectable stage III colorectal cancer |
| Q37073448 | Colorectal cancer treatment in older patients. |
| Q38644154 | Combination Adjuvant Chemotherapy with Targeted Drugs for Treatment of Colorectal Cancer: A Network Meta-Analysis. |
| Q80265749 | Combination therapy of S-1 and CDDP for patients with colorectal cancer |
| Q36610915 | Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. |
| Q33638615 | Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report |
| Q36487348 | Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers |
| Q33874203 | Cost implications of new treatments for advanced colorectal cancer. |
| Q36609698 | Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment |
| Q44913737 | Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma |
| Q42775518 | Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept |
| Q36832121 | Current role of antibody therapy in patients with metastatic colorectal cancer. |
| Q37077225 | Current status of adjuvant therapy for colon cancer. |
| Q37990061 | DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment. |
| Q53232788 | Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. |
| Q54571851 | Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. |
| Q37595260 | Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients. |
| Q35967416 | Drug rechallenge and treatment beyond progression--implications for drug resistance. |
| Q87888600 | ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis |
| Q57758061 | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making |
| Q50797877 | Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. |
| Q50085723 | Effect of Adjuvant Chemotherapy on Elderly Colorectal Cancer Patients: Lack of Evidence |
| Q37133361 | Effectiveness of adjuvant chemotherapy for elderly patients with lymph node-positive colorectal cancer. |
| Q46113172 | Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin |
| Q41015601 | Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases |
| Q37401666 | Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer. |
| Q26752747 | Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases |
| Q45233225 | Evolution of FOLFOX regimens in the treatment of advanced colorectal cancer. |
| Q37372475 | Evolution of nonsurgical therapy for colorectal cancer |
| Q37360585 | Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy |
| Q35629061 | First-line treatment strategies to improve survival in patients with advanced colorectal cancer |
| Q28659746 | Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells |
| Q36070191 | Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer |
| Q84807162 | Hepatic Intra-Arterial Injection of Drug-Eluting Bead, Irinotecan (DEBIRI) in Unresectable Colorectal Liver Metastases Refractory to Systemic Chemotherapy: Results of Multi-Institutional Study |
| Q37123700 | Hypersensitivity reactions to oxaliplatin and other antineoplastic agents |
| Q44230226 | Hypersensitivity reactions to oxaliplatin in two asian patients |
| Q42007876 | Identification of responders/non-responders to 5-fluorouracil based on individual 50% inhibitory area under the concentration curve of 5-fluorouracil obtained with collagen gel droplet-embedded culture-drug sensitivity test in colorectal cancer |
| Q39202110 | Individualized chemotherapy for colorectal cancer based on the collagen gel droplet-embedded drug sensitivity test |
| Q33845577 | Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin |
| Q33384357 | Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer |
| Q37662806 | Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients |
| Q85785131 | Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival |
| Q40087710 | Is intensive chemotherapy safe for rural cancer patients? |
| Q61868148 | Is oxaliplatin the optimal platinum agent in gastric cancer? |
| Q36300533 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer |
| Q37946252 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. |
| Q36324953 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. |
| Q92776508 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer |
| Q35798161 | Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T |
| Q35746556 | Locoregional therapy and systemic cetuximab to treat colorectal liver metastases |
| Q46038495 | Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer. |
| Q35076194 | Medical treatment of advanced colorectal cancer in 2009. |
| Q36893806 | Metastatic colorectal cancer-past, progress and future |
| Q36920617 | Metastatic colorectal cancer: current systemic treatment options. |
| Q37975508 | Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach--present status |
| Q39392750 | MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers |
| Q40202250 | Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver |
| Q35340865 | Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer. |
| Q37926477 | Molecular mechanisms of cisplatin resistance |
| Q90291999 | Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study) |
| Q37318017 | Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients |
| Q36695803 | Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. |
| Q35019148 | Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice |
| Q36848090 | Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial |
| Q38112587 | New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy |
| Q35594038 | Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived |
| Q36677474 | Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells. |
| Q36499255 | Optimal treatment of metastatic colorectal cancer |
| Q37782046 | Optimizing resection for “responding” hepatic metastases after neoadjuvant chemotherapy |
| Q38338989 | Outcomes and endpoints in cancer trials: bridging the divide |
| Q37220492 | Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer |
| Q36788436 | Oxaliplatin in the treatment of colorectal cancer |
| Q33387297 | Oxaliplatin with biweekly low dose leucovorin and bolus and continuous infusion of 5-fluorouracil (modified FOLFOX 4) as a salvage therapy for patients with advanced gastric cancer |
| Q35980222 | Oxaliplatin-associated neuropathy: a review |
| Q37242664 | Oxaliplatin-based chemotherapy in the management of colorectal cancer |
| Q37965616 | Oxaliplatin: a review of approved uses. |
| Q35214568 | Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer |
| Q36627275 | Panitumumab in colon cancer: a review and summary of ongoing trials |
| Q38371340 | Patient-reported outcomes as end points and outcome indicators in solid tumours |
| Q36375924 | Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies |
| Q34731381 | Personalized colon cancer care in 2010. |
| Q46502256 | Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene |
| Q35563540 | Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. |
| Q36677787 | Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine |
| Q35025710 | Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients. |
| Q33387187 | Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors |
| Q24644011 | Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies |
| Q46798803 | Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. |
| Q33378863 | Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer |
| Q86646645 | Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701) |
| Q33746897 | Phase II study of irinotecan, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as first-line therapy |
| Q37341645 | Phase II study of oxaliplatin, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as second line therapy |
| Q46981846 | Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy |
| Q34606724 | Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. |
| Q82032854 | Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer |
| Q46823324 | Planning transarterial radioembolization of colorectal liver metastases with Yttrium 90 microspheres: evaluation of a sequential diagnostic approach using radiologic and nuclear medicine imaging techniques |
| Q38521636 | Platinum hypersensitivity and desensitization |
| Q37287044 | Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. |
| Q33826355 | Predicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradation |
| Q38541188 | Presentation and Diagnosis of Hypersensitivity to Platinum Drugs |
| Q38931361 | Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics. |
| Q51741261 | Prevention of peritoneal carcinomatosis in mice with combination hyperthermal intraperitoneal chemotherapy and IL-2. |
| Q34018266 | Primary site resection is superior for incurable metastatic colorectal cancer |
| Q33931049 | Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases |
| Q36616519 | Recent advances in the systemic management of colorectal cancer |
| Q89338392 | Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients |
| Q36843760 | Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. |
| Q28301157 | Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage |
| Q37859220 | Reintroduction of oxaliplatin: a viable approach to the long-term management of metastatic colorectal cancer |
| Q35544078 | Review article: colorectal cancer chemotherapy |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q34335452 | Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer. |
| Q37230238 | Role of oxaliplatin in the treatment of colorectal cancer |
| Q34113977 | S100A10 protein expression is associated with oxaliplatin sensitivity in human colorectal cancer cells |
| Q46171621 | SEOM clinical guidelines for the treatment of advanced colorectal cancer 2013. |
| Q51644226 | SEOM clinical guidelines for the treatment of advanced colorectal cancer. |
| Q36424039 | SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm |
| Q34023788 | Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies |
| Q33370361 | SarCNU in recurrent or metastatic colorectal cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group |
| Q28972468 | Satraplatin: leading the new generation of oral platinum agents |
| Q24241235 | Second-line chemotherapy in advanced and metastatic CRC |
| Q30238760 | Second-line systemic therapy for metastatic colorectal cancer. |
| Q43191517 | Second-line therapy for advanced colorectal cancer. |
| Q36104931 | Second-line therapy for advanced colorectal carcinoma. |
| Q46965188 | Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer |
| Q24234461 | Sequential versus combination chemotherapy for advanced colorectal cancer |
| Q34581085 | Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial |
| Q36790166 | Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases |
| Q50575635 | Short-term and long-term outcomes after simultaneous resection of colorectal malignancies and synchronous liver metastases. |
| Q90643949 | Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusion |
| Q33622783 | Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study |
| Q36832322 | Surgical therapy for colorectal metastases to the liver |
| Q38228850 | Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials |
| Q24815800 | Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer |
| Q46987043 | Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis |
| Q42705208 | Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights |
| Q38627295 | Synchronous colorectal liver metastases: focus on the elderly : An Effectiveness Study from Routine Care. |
| Q58614342 | Systemic Therapy for Patients with Colorectal Cancer: State of the Art |
| Q37345922 | Systemic and targeted therapy for advanced colon cancer |
| Q37037106 | Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement |
| Q81253030 | Systemic treatment of colorectal cancer |
| Q36391430 | Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancer |
| Q36217126 | Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report |
| Q36564975 | Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. |
| Q36374590 | Technical considerations in percutaneous hepatic perfusion--a multi-center experience |
| Q93185144 | The effect of MTHFD2 on the proliferation and migration of colorectal cancer cell lines |
| Q42948409 | The effect on the small bowel of 5-FU and oxaliplatin in combination with radiation using a microcolony survival assay |
| Q37111231 | The impact of chemotherapy on overall survival and quality of life of patients with metastatic colorectal cancer: a review of phase III trials |
| Q52591422 | The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review. |
| Q36634272 | The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies. |
| Q81099536 | The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study |
| Q34649255 | The resurgence of platinum-based cancer chemotherapy |
| Q46598899 | The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients |
| Q37833645 | The role of bevacizumab in colorectal cancer: understanding its benefits and limitations |
| Q33284711 | The role of primary tumour resection in patients with stage IV colorectal cancer |
| Q34214957 | Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers |
| Q37407250 | Transarterial Chemoembolization of Metastatic Colorectal Carcinoma with Drug-Eluting Beads, Irinotecan (DEBIRI): Multi-Institutional Registry |
| Q44027955 | Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population |
| Q80761707 | Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin? |
| Q39371177 | Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion |
| Q38228522 | Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. |
| Q36276360 | Treatment of elderly cancer patients with chemotherapy |
| Q37298994 | Treatment of the elderly colorectal cancer patient: SIOG expert recommendations |
| Q34242959 | Using Drosophila melanogaster to identify chemotherapy toxicity genes |
| Q92996657 | Variability of Oxaliplatin-Induced Neuropathic Pain Symptoms in Each Cycle and Its Implications on the Management of Colorectal Cancer Patients: A Retrospective Study in South Western Sydney Local Health District Hospitals, Sydney, Australia |
| Q41894430 | When is a line not a line? |
| Q38235941 | Which strategy after first-line therapy in advanced colorectal cancer? |
| Q37425429 | XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center |
| Q79769145 | [A review of chemotherapy for metastatic colon cancer] |
| Q39006039 | trans,cis,cis-bis(benzoato)dichlorido(cyclohexane-1R,2R-diamine)platinum(IV): a prodrug candidate for the treatment of oxaliplatin-refractory colorectal cancer |
Search more.